FDA
-
-
-
-
-
-
-
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
-
-
-
-
-
-
-
Ainos (AIMD) Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
-
-
-
-
-
-
-
Ainos (AIMD) Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
-
-
-
-
-
-
-
Ainos (AIMD) Granted FDA Orphan Drug Designation for VELDONA
-
-
-
-
-
-
-
Ainos (AIMD) Submits INDA to FDA for Phase 2 Trial of VELDONA
-
-
-
-
-
332,018 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

